Investors

Kadimastem Announces Executive Management Changes

​

Encouraging Results of Cohort B of its Phase 1/2a Clinical Trial of AstroRx® for ALS

​

Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in

​

Kadimastem Appoints Ruth Alon as Chairperson of the Company's Board of Directors

​

Kadimastem Announces Promising Results of Cohort A of its Phase 1/2a Clinical Trial in ALS

​

Kadimastem Announces the Completion of Treatment for Cohort B

​

Successful Preclinical results of our Cell Therapy Treatment for Insulin-Dependent Diabetes

​

Kadimastem to Submit an Amendment of its ALS Phase 1/2a Clinical Trial Protocol

​

Kadimastem to Present at the 7th International Stem Cell Meeting, in Tel-Aviv

​

Kadimastem Announces Promising Interim Results of Cohort A of its Phase 1/2a Clinical Trial in ALS

​

Kadimastem Announces Leadership Changes

​

Kadimastem receives Approval from the Ministry of Health of Israel to continue its trial of AstroRX®

​

Appointment of a new CFO for Kadimastem

​

Kadimastem Announces the Completion of Cell Transplantation of AstroRx® in ALS Patients for Cohort A

​

2019 Israel Innovation Authority Budget Approved for Kadimastem: NIS 13.6 M for ALS Project

​

Kadimastem to be included in the TASE Indices

​

Success for Kadimastem: 97% of Warrants (Series 4) Exercised for NIS 3.6M

​

Kadimastem and Defymed Awarded Grant for the Development of a Product for the Treatment of Diabetes

​

FDA Granted Kadimastem Orphan Drug Status for AstroRx® for the Treatment of ALS

​

Medical Breakthrough on a Global Scale and Significant Achievement for Kadimastem:

​

Altshuler Shaham and Company Stakeholders Lead $5.15 Million Investment in Kadimastem

​

Kadimastem and The AFDR Selected to Receive a bi-National Grant

​

Kadimastem has Upgraded its Manufacturing Site for Treatment of ALS Patients in the Clinical Trial

​

Kadimastem was honored with a prize for excellence for the presentation of the company's technology

​

Initiation of coverage report on Kadimastem by global research firm Frost & Sullivan:

​

Scientific Article by Kadimastem: Cell-Based Treatment for ALS was Published

​

Successful Public Offering for Kadimastem

​

Kadimastem Announces the Enrollment of the First Patient for Its Clinical Trial in ALS Patients

​

Kadimastem Collaborates with French SME Defymed to Validate a Combined Solution for Type 1 Diabetes

​

Successful Rights Offering for Kadimastem; Raised NIS 5.1M

​

Kadimastem to Raise up to NIS 10M in Rights Offering

​

Kadimastem Received Response from FDA:

​

Kadimastem Approached the FDA Regarding Its ALS Treatment

​

Kadimastem to collaborate with Merck Serono to advance efforts in neurodegenerative diseases

​

Chief Scientist Increases Budget to Advance Kadimastem's Cell Therapy for ALS

​

Success in Kadimastem’s First Pre-Clinical Trial for Treatment of Amyotrophic Lateral Sclerosis (ALS

​

Kadimastem Receives Approval for U.S. Patent

​

Leading pharma entrepreneur Avi Meizler believes in Kadimastem!

​

Kadimastem announces its intention to reduce the exercise price for warrants (Series 1)

​

Kadimastem Augments the Company's ALS Activities

​

Kadimastem has received approval from the OCS to promote cell therapy

​

Merck Serono and Kadimastem MOU on Drug Screening and Discovery for Neurodegenerative Diseases

​

Kadimastem successfully completes an IPO and raised $5.5 Million USD

​

Pharmaceutical Company Merck Serono signs an agreement: Use Kadimastem's platform for drug screening

​

Dr. Eli Opper, joined Kadimastem's team of Advisors

​

Kadimastem appointed Mr. Ofer Haviv as a director

​

The new Chief Scientist, Mr. Avi Hasson visits Kadimastem

​

The Chief Scientist visits Kadimastem

​